Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.
OBJECTIVE
To address the possibility that sennoside B inhibition of cell proliferation is mediated via interference with platelet-derived growth factor (PDGF) signaling.


METHODS
Human osteosarcoma MG63 cells were treated with PDGF in the presence or absence of sennoside B. Activation of the PDGF signaling pathway was monitored using western immunoblotting with specific antibodies against the PDGF receptor, phosphotyrosine and components of the downstream signaling cascade. Activation of cell metabolism and proliferation was assessed by chromogenic reduction of MTT.


RESULTS
Sennoside B was found to inhibit PDGF-BB-induced phosphorylation of the PDGF receptor (PDGFR) in human MG63 osteosarcoma cells. Downstream signaling was also affected; pre-incubation of PDGF-BB with sennoside B inhibited the phosphorylation of pathway components including Ak strain transforming protein (AKT), signal transducer and activator of transcription 5 (STAT-5) and extracellular signal-regulated kinase 1/2 (ERK1/2). Further, we found that sennoside B can bind directly to the extracellular domains of both PDGF-BB and the PDGF-beta receptor (PDGFR-beta). The effect was specific for sennoside B; other similar compounds including aloe-emodin, rhein and the meso isomer (sennoside A) failed to inhibit PDGFR activation or downstream signaling. Sennoside B also inhibited PDGF-BB stimulation of MG63 cell proliferation.


CONCLUSIONS
These results indicate that sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway. Sennoside B is therefore of potential utility in the treatment of proliferative diseases in which PDGF signaling plays a central role.
Chen
Yen-Chun
YC
Biomedical Engineering Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan. YenChunChen@itri.org.tw
Chang
Chia-Ni
CN
Hsu
Hui-Chun
HC
Chiou
Shu-Jiau
SJ
Lee
Lain-Tze
LT
Hseu
Tzong-Hsiung
TH
D000880:Anthraquinones / Q000378:metabolism / Q000494:pharmacology*; D000077214:Becaplermin; D002400:Cathartics / Q000378:metabolism / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D012516:Osteosarcoma / Q000188:drug therapy; D010766:Phosphorylation / Q000187:drug effects; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D020574:Proto-Oncogene Proteins c-sis; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000037:antagonists & inhibitors / Q000378:metabolism; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D050799:STAT5 Transcription Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D012676:Senna Extract; D000081226:Sennosides; D015398:Signal Transduction / Q000187:drug effects
D000880:Anthraquinones; D002400:Cathartics; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D050799:STAT5 Transcription Factor; D000081226:Sennosides; D000077214:Becaplermin; D012676:Senna Extract; D020797:Receptor, Platelet-Derived Growth Factor beta; D017479:Receptors, Platelet-Derived Growth Factor; D051058:Oncogene Protein v-akt; D048049:Extracellular Signal-Regulated MAP Kinases